>Mercado de vectores lentivirales en Oriente Medio y África, por componente (promotor lentiviral, etiquetas de fusión lentiviral, sistemas de empaquetado lentiviral, otros), tipo (producto, servicios), generación (cuarta generación, tercera generación, segunda generación, primera generación), flujo de trabajo (procesamiento ascendente, procesamiento descendente), método de administración (in vivo, ex vivo), indicación de enfermedad (cáncer, trastornos genéticos, enfermedades infecciosas, enfermedades veterinarias, otras), aplicación (terapia génica, vacunología), usuario final (empresas de biotecnología, empresas farmacéuticas, organizaciones de investigación por contrato, organización de desarrollo y fabricación por contrato (CDMO), institutos académicos/de investigación), país (Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel y el resto de Oriente Medio y África) Tendencias y pronóstico de la industria 2028
Análisis y perspectivas del mercado : mercado de vectores lentivirales en Oriente Medio y África
Se espera que el mercado de vectores lentivirales gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 16,1% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 207,37 millones para 2028. La creciente demanda de vectores lentivirales y el aumento de las enfermedades infecciosas son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
Los vectores lentivirales (LV) son vehículos eficientes para la transferencia de genes en células de mamíferos debido a su capacidad de expresar de manera estable un gen de interés en células que no se dividen y en células que se dividen. Los lentivirus son patógenos humanos y animales que se sabe que tienen largos períodos de incubación e infección persistente. El tiempo entre la infección inicial y la aparición de los primeros síntomas puede alcanzar varios meses o años.
Los biólogos moleculares utilizan con frecuencia vectores virales para introducir material genético en las células. Este procedimiento puede llevarse a cabo in vivo (dentro de un organismo vivo) o en un cultivo celular (in vitro). Los virus han desarrollado mecanismos moleculares especializados para transportar sus genomas de manera eficiente dentro de las células que infectan.
El aumento de la población geriátrica y la demanda de desarrollos de vacunas durante la emergencia de Covid-19 ayudan de manera efectiva al crecimiento del mercado de vectores lentivirales. Sin embargo, la falta de escalabilidad y las limitaciones de la purificación posterior de los vectores lentivirales pueden obstaculizar el crecimiento futuro de un mercado de vectores lentivirales. Las iniciativas estratégicas de los principales actores del mercado y el aumento de la financiación para la genómica actúan como una oportunidad para el crecimiento del mercado de vectores lentivirales en Asia y el Pacífico. Las estrictas políticas regulatorias y los efectos secundarios asociados con los productos de vectores lentivirales actúan como un desafío para el crecimiento futuro del mercado.
El informe de mercado de vectores lentivirales proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de vectores lentivirales en Oriente Medio y África
El mercado de vectores lentivirales está segmentado en ocho segmentos notables que se basan en el componente, el tipo, la generación, el flujo de trabajo, el método de administración, la indicación de la enfermedad, la aplicación y el usuario final. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- En función de los componentes, el mercado de vectores lentivirales se segmenta en promotores lentivirales, etiquetas de fusión lentivirales, sistemas de empaquetado de lentivirus y otros. En 2021, se espera que el segmento de sistemas de empaquetado de lentivirus domine el mercado de vectores lentivirales debido al aumento del gasto en atención médica.
- Según el tipo, el mercado de vectores lentivirales se segmenta en productos y servicios. En 2021, se espera que el segmento de productos domine el mercado de vectores lentivirales debido a la alta incidencia de enfermedades genéticas.
- Sobre la base de la generación, el mercado de vectores lentivirales se segmenta en cuarta generación, tercera generación, segunda generación y primera generación. En 2021, se espera que el segmento de cuarta generación domine el mercado de vectores lentivirales debido a las vigorosas actividades de investigación y desarrollo.
- Sobre la base del flujo de trabajo, el mercado de vectores lentivirales se segmenta en procesamiento ascendente y procesamiento descendente. En 2021, se espera que el segmento de procesamiento ascendente domine el mercado de vectores lentivirales debido al avance de la tecnología.
- Según el método de administración, el mercado de vectores lentivirales se segmenta en in vivo y ex vivo. En 2021, se espera que el segmento in vivo domine el mercado de vectores lentivirales debido a una mayor eficiencia.
- En función de la indicación de la enfermedad, el mercado de vectores lentivirales se segmenta en cáncer, trastornos genéticos, enfermedades infecciosas , enfermedades veterinarias y otras. En 2021, se espera que el segmento del cáncer domine el mercado de vectores lentivirales debido al aumento de casos de cáncer y geriátricos en la región de Oriente Medio y África.
- Sobre la base de la aplicación, el mercado de vectores lentivirales se segmenta en terapia génica y vaccinología. En 2021, se espera que el segmento de terapia génica domine el mercado de vectores lentivirales debido a la creciente conciencia de la terapia génica y la creciente aprobación de ensayos clínicos.
- On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government funds for gene therapy research and development department.
Lentiviral Vector Market Country Level Analysis
The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the lentiviral vector market report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, rest of Middle East and Africa.
Upstream processing segment in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of rising investments for research activities. South Africa is leading the growth of the Middle East and Africa market and up-stream processing segment is dominating in this region due to rising funding by government for technological improvements in R & D activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market
Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lentiviral Vector Market Share Analysis
El panorama competitivo del mercado de vectores lentivirales proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de vectores lentivirales.
Las principales empresas que participan en el informe de mercado de vectores lentivirales son Merck KGaA, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, System Biosciences, LLC, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Lonza, entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de vectores lentivirales.
Por ejemplo,
- En febrero de 2021, Thermo Fisher Scientific Inc. anunció que había ganado seis premios en los premios anuales CMO Leadership Awards. Los premios, otorgados por Life Science Leader y Outsourced Pharma, reconocen a los principales socios de fabricación por contrato según la evaluación de las empresas biofarmacéuticas y biotecnológicas. Se estima que este reconocimiento fortalecerá su presencia a nivel mundial y conducirá a un repunte de su crecimiento en los próximos años.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la presencia de la empresa en el mercado de vectores lentivirales, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPONENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW
4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE
4.2.1 PRODUCT
4.2.2 SERVICES
5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK
5.1 REGULATION IN THE UNITED STATES
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN DEMAND FOR VIRAL VECTORS
6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES
6.1.5 GROWING GERIATRIC POPULATION
6.2 RESTRAINTS
6.2.1 LACK OF SCALABILITY
6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
6.2.3 SHORTAGE OF SKILLED PERSONNELS
6.3 OPPORTUNITIES
6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS
6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT
6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES
6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION
7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 LENTIVIRUS PACKAGING SYSTEMS
8.3 LENTIVIRAL PROMOTER
8.3.1 LENTIVIRUS PROMOTER VECTORS
8.3.2 LENTIVIRUS PROMOTERLESS VECTORS
8.4 LENTIVIRAL FUSION TAGS
8.5 OTHERS
9 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRODUCT
9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)
9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)
9.3 SERVICES
10 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION
10.1 OVERVIEW
10.2 4TH GENERATION
10.3 3RD GENERATION
10.4 2ND GENERATION
10.5 1ST GENERATION
11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION & EXPANSION
11.2.2 VECTOR RECOVERY/ HARVESTING
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILL-FINISH
12 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 IN-VIVO
12.3 EX-VIVO
13 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 B-THALESSEMIA
13.3.2 X-LINKED ADRENO LEUKODYSTROPHY
13.3.3 METACHROMATIC LEUKODYSTROPHY
13.3.4 WISKOTT-ALDRICH SYNDROME
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 HIV
13.4.2 OTHERS
13.5 VETERINARY DISEASES
13.6 OTHERS
14 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 GENE THERAPY
14.2.1 RECOMBINANT PROTEIN EXPRESSION
14.2.2 FUNCTIONAL ASSAYS
14.2.3 IN VITRO TRANSCRIPTION
14.2.4 PROTEIN CHARACTERIZATION
14.2.5 OTHERS
14.3 VACCINOLOGY
15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER
15.1 OVERVIEW
15.2 ACADEMIC/ RESEARCH INSTITUTES
15.3 PHARMACEUTICAL COMPANIES
15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
15.5 BIOTECHNOLOGY COMPANIES
15.6 CONTRACT RESEARCH ORGANIZATIONS
16 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 U.A.E.
16.1.4 EGYPT
16.1.5 ISRAEL
16.1.6 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT
19 COMPANY PROFILE
19.1 OXFORD BIOMEDICA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 MERCK KGAA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LONZA
19.4.1 COMPANY SNAPSHOT
19.4.2 RECENT ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 CYTIVA (A SUBSIDIARY OF DANAHER)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 APPLIED BIOLOGICAL MATERIALS INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BATAVIA BIOSCIENCES B.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEBIRD BIO, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 CELL BIOLABS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CREATIVE BIOLABS
19.10.1 COMPANY SNAPSHOT
19.10.2 SERVICE PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 COBRA BIOLOGICS LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 FINVECTOR OY
19.12.1 COMPANY SNAPSHOT
19.12.2 SERVICE PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
19.13.1 COMPANY SNAPSHOT
19.13.2 RECENT ANALYSIS
19.13.3 SERVICE PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 GENEMEDI
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ORIGENE TECHNOLOGIES, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 SINO BIOLOGICAL, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SIRION-BIOTECH GMBH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SYSTEM BIOSCIENCES, LLC
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 TAKARA BIO INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WAISMAN BIOMANUFACTURING
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 THERMO FISHER SCIENTIFIC
TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
TABLE 3 KERAFAST
TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.
TABLE 5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 U.A.E. LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 93 U.A.E. LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 94 U.A.E. LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.A.E. PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.A.E. LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 97 U.A.E. LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 98 U.A.E. UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 99 U.A.E. DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 100 U.A.E. LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 101 U.A.E. LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 102 U.A.E. GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 103 U.A.E. INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 104 U.A.E. LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 U.A.E. GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 U.A.E. LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 107 EGYPT LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 108 EGYPT LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 109 EGYPT LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 EGYPT PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 EGYPT LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 112 EGYPT LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 113 EGYPT UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 114 EGYPT DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 115 EGYPT LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 116 EGYPT LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 117 EGYPT GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 118 EGYPT INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 120 EGYPT GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 121 EGYPT LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 127 ISRAEL LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 128 ISRAEL UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 129 ISRAEL DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 130 ISRAEL LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 REST OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
FIGURE 15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020
FIGURE 16 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020
FIGURE 24 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020
FIGURE 28 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020
FIGURE 32 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020
FIGURE 36 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020
FIGURE 40 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, 2020
FIGURE 44 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)
FIGURE 48 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)
FIGURE 49 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)
FIGURE 52 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
